Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03419559
Other study ID # IOV-LUN-201
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date February 28, 2018
Est. completion date December 2024

Study information

Verified date April 2019
Source Iovance Biotherapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a Phase 2, open-label, multicenter study evaluating adoptive cell therapy (ACT) with autologous TIL therapy (LN-145) in combination with Anti-PD-L1 inhibitor durvalumab.


Description:

LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI. The cell transfer therapy used in this study involves patients receiving a nonmyeloablative (NMA) lymphocyte depleting preparative regimen, followed by infusion of autologous TIL followed by the administration of a regimen of IL-2.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2024
Est. primary completion date December 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Confirmed diagnosis of Stage III or Stage IV NSCLC and progressed after = 3 lines of prior systemic therapy in the locally advanced or metastatic setting

- Have at least 1 lesion resectable for TIL generation

- Measurable disease as defined by RECIST v1.1

- Male or female, = 18 years of age

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and estimated life expectancy of = 3 months

- Adequate bone marrow function at screening

- Adequate organ function at screening

- A washout period from prior anticancer therapy(ies) of a minimum duration is required prior to first study treatment

- Recovered from all prior anticancer therapy-related AEs to Grade 1 or less (per CTCAE v4.03) prior to enrollment

- Female patients of childbearing potential and male patients with partners of childbearing potential patient must agree to use contraception while on study and during the timeframes as specified following the last dose of study drug(s) received, or until the first dose of the subsequent anticancer therapy, whichever is longer

- Evidence of postmenopausal status or negative urine or serum pregnancy test for female premenopausal patients

Exclusion Criteria:

- History of other malignancies, except for the following: adequately treated nonmelanoma skin cancer, curatively treated in-situ cancer of the cervix, curatively-treated thyroid cancer, or other solid tumors curatively treated with no evidence of disease for = 3 years

- Patients who have received prior cell therapy

- Patients who have received prior checkpoint inhibitors: such as anti-PD-1, anti-PD-L1 inhibitors, and durvalumab

- Active or prior documented autoimmune or inflammatory disorders

- History of primary or acquired immunodeficiency syndrome, history of allogeneic organ transplant that requires therapeutic immunosuppression

- Received live or attenuated vaccination within 28 days prior to the start of NMA-LD

- Patients with a history of hypersensitivity to any component of the study drugs

- Mean QT interval = 470 msec

- Patients who have a left ventricular ejection fraction (LVEF) of < 45% or who are New York Heart Association (NYHA) Class 2 or higher

- Serious illnesses or medical conditions, which would pose increased risk for study participation and/or compliance with the protocol

- Patients who have obstructive or restrictive pulmonary disease and have a documented FEV1 (forced expiratory volume in 1 second) of = 60%

- Active central nervous system metastases and/or leptomeningeal disease

- Female patients who are pregnant or breastfeeding

- Active infection including tuberculosis (TB), hepatitis B, hepatitis C, or HIV

- Current or prior use of immunosuppressive medication within 28 days before the first dose of study treatment, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid

Study Design


Intervention

Biological:
LN-145
adoptive cell therapy (ACT) with autologous TIL therapy
Drug:
Durvalumab
PD-L1 antagonist monoclonal antibody

Locations

Country Name City State
United States Karmanos Cancer Institute Detroit Michigan
United States University of California San Diego, Moores Cancer Center La Jolla California
United States University of California, Los Angeles, Santa Monica Hematology/Oncology Los Angeles California
United States University of Louisville James Graham Brown Cancer Center Louisville Kentucky
United States Morristown Medical Center Atlantic Hematology Oncology Morristown New Jersey
United States Vanderbilt University Nashville Tennessee
United States UPMC Cancer Center Pittsburgh Pennsylvania
United States University of Washington Medical Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Iovance Biotherapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate To evaluate efficacy using the objective response rate (ORR) A maximum of 24 months
Primary = Grade 3 Treatment-Emergent Adverse Event To evaluate the safety as measured by any = Grade 3 treatment-emergent adverse event (TEAE) rate A maximum of 24 months
Secondary Duration of Response To further evaluate efficacy such as the duration of response (DOR) A maximum of 24 months
Secondary Progression Free Survival To further evaluate efficacy such as progression free survival (PFS) A maximum of 24 months
Secondary Overall Survival To further evaluate efficacy such as overall survival (OS) A minimum of 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Completed NCT01945021 - Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Phase 2
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Terminated NCT04022876 - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Phase 1
Recruiting NCT05898763 - TEIPP Immunotherapy in Patients With NSCLC Phase 1/Phase 2
Recruiting NCT05532696 - Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients Phase 1/Phase 2
Completed NCT04311034 - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Completed NCT00349089 - Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04571632 - Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors Phase 2
Terminated NCT03599518 - DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06020989 - Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy Phase 2
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1
Withdrawn NCT03574649 - QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02844140 - DE-CT in Lung Cancer Proton Therapy N/A
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1